{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.16","value":"86.61"},{"groupId":"OG001","spread":"18.05","value":"86.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"559"},{"groupId":"OG001","value":"567"}],"units":"Participants"}],"title":"TOI Score, Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.03","value":"0.46"},{"groupId":"OG001","spread":"15.95","value":"2.18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"514"},{"groupId":"OG001","value":"497"}],"units":"Participants"}],"title":"TOI Score Change, Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.00","value":"2.91"},{"groupId":"OG001","spread":"16.71","value":"4.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"485"},{"groupId":"OG001","value":"481"}],"units":"Participants"}],"title":"TOI Score Change, End Induction"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.16","value":"6.22"},{"groupId":"OG001","spread":"16.57","value":"7.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"363"},{"groupId":"OG001","value":"400"}],"units":"Participants"}],"title":"TOI Score Change, Maint M2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.62","value":"7.61"},{"groupId":"OG001","spread":"16.75","value":"7.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"362"},{"groupId":"OG001","value":"408"}],"units":"Participants"}],"title":"TOI Score Change, Maint M12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.06","value":"6.23"},{"groupId":"OG001","spread":"16.96","value":"7.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"412"},{"groupId":"OG001","value":"440"}],"units":"Participants"}],"title":"TOI Score Change, End Maint"}],"denoms":[{"counts":[{"groupId":"OG000","value":"559"},{"groupId":"OG001","value":"567"}],"units":"Participants"}],"description":"The FACT-Lym TOI Score for the follicular lymphoma population was derived from the following 3 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym TOI Score is the sum of the 3 individual subscales (range 0-116). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period was followed by either a maintenance or observation period for responders or non-responders, respectively. Responders received rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders received no protocol specified treatment during the 2-year observation period. Finally, participants were followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant was chosen by the site prior to initiation of the study.","id":"OG000","title":"Rituximab+Chemotherapy"},{"description":"Participants received either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period was followed by either a maintenance or observation period for responders or non-responders, respectively. Responders received obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders received no protocol specified treatment during the 2-year observation period. Finally, participants were followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant was chosen by the site prior to initiation of the study.","id":"OG001","title":"Obinutuzumab+Chemotherapy"}],"paramType":"MEAN","populationDescription":"The FL ITT population was defined as all randomized participants with follicular histology grouped according to their randomized treatment arm regardless of what treatments were actually received.","reportingStatus":"POSTED","timeFrame":"Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)","title":"Change From Baseline in FACT-Lym Total Outcome Index (TOI) Score (Follicular Lymphoma Population)","type":"SECONDARY","unitOfMeasure":"units on a scale"}